ID   CGL_HUMAN               Reviewed;         405 AA.
AC   P32929; B4E1R2; E9PDV0; Q53FB3; Q53Y79; Q9H4W7; Q9H4W8;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   10-JAN-2003, sequence version 3.
DT   10-MAY-2017, entry version 178.
DE   RecName: Full=Cystathionine gamma-lyase;
DE            EC=4.4.1.1;
DE   AltName: Full=Cysteine-protein sulfhydrase;
DE   AltName: Full=Gamma-cystathionase;
GN   Name=CTH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANT ILE-403.
RC   TISSUE=Liver;
RX   PubMed=1339280; DOI=10.1016/0006-291X(92)92265-Y;
RA   Lu Y., O'Dowd B.F., Orrego H., Israel Y.;
RT   "Cloning and nucleotide sequence of human liver cDNA encoding for
RT   cystathionine gamma-lyase.";
RL   Biochem. Biophys. Res. Commun. 189:749-758(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT
RP   ILE-403.
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ILE-403.
RC   TISSUE=Kidney;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   CATALYTIC ACTIVITY, SUBUNIT, COFACTOR, ENZYME REGULATION, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10212249; DOI=10.1074/jbc.274.18.12675;
RA   Steegborn C., Clausen T., Sondermann P., Jacob U., Worbs M.,
RA   Marinkovic S., Huber R., Wahl M.C.;
RT   "Kinetics and inhibition of recombinant human cystathionine gamma-
RT   lyase. Toward the rational control of transsulfuration.";
RL   J. Biol. Chem. 274:12675-12684(1999).
RN   [9]
RP   FUNCTION.
RX   PubMed=19261609; DOI=10.1074/jbc.M808026200;
RA   Chiku T., Padovani D., Zhu W., Singh S., Vitvitsky V., Banerjee R.;
RT   "H2S biogenesis by human cystathionine gamma-lyase leads to the novel
RT   sulfur metabolites lanthionine and homolanthionine and is responsive
RT   to the grade of hyperhomocysteinemia.";
RL   J. Biol. Chem. 284:11601-11612(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   FUNCTION AS CYSTEINE-PROTEIN SULFHYDRASE.
RX   PubMed=22169477; DOI=10.1126/scisignal.2002329;
RA   Krishnan N., Fu C., Pappin D.J., Tonks N.K.;
RT   "H2s-induced sulfhydration of the phosphatase PTP1B and its role in
RT   the endoplasmic reticulum stress response.";
RL   Sci. Signal. 4:RA86-RA86(2011).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-402 IN COMPLEXES WITH
RP   PYRODOXAL PHOSPHATE; NITRATE AND PROPARGYLGLYCINE, FUNCTION, SUBUNIT,
RP   ENZYME REGULATION, CATALYTIC ACTIVITY, AND COFACTOR.
RX   PubMed=19019829; DOI=10.1074/jbc.M805459200;
RA   Sun Q., Collins R., Huang S., Holmberg-Schiavone L., Anand G.S.,
RA   Tan C.-H., van-den-Berg S., Deng L.-W., Moore P.K., Karlberg T.,
RA   Sivaraman J.;
RT   "Structural basis for the inhibition mechanism of human cystathionine
RT   gamma-lyase, an enzyme responsible for the production of H(2)S.";
RL   J. Biol. Chem. 284:3076-3085(2009).
RN   [14]
RP   VARIANTS CSTNU ILE-67 AND GLU-240, AND VARIANT ILE-403.
RX   PubMed=12574942; DOI=10.1007/s00439-003-0906-8;
RA   Wang J., Hegele R.A.;
RT   "Genomic basis of cystathioninuria (MIM 219500) revealed by multiple
RT   mutations in cystathionine gamma-lyase (CTH).";
RL   Hum. Genet. 112:404-408(2003).
RN   [15]
RP   CHARACTERIZATION OF VARIANTS CSTNU ILE-67 AND GLU-240, COFACTOR,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.
RX   PubMed=18476726; DOI=10.1021/bi800351a;
RA   Zhu W., Lin A., Banerjee R.;
RT   "Kinetic properties of polymorphic variants and pathogenic mutants in
RT   human cystathionine gamma-lyase.";
RL   Biochemistry 47:6226-6232(2008).
CC   -!- FUNCTION: Catalyzes the last step in the trans-sulfuration pathway
CC       from methionine to cysteine. Has broad substrate specificity.
CC       Converts cystathionine to cysteine, ammonia and 2-oxobutanoate.
CC       Converts two cysteine molecules to lanthionine and hydrogen
CC       sulfide. Can also accept homocysteine as substrate. Specificity
CC       depends on the levels of the endogenous substrates. Generates the
CC       endogenous signaling molecule hydrogen sulfide (H2S), and so
CC       contributes to the regulation of blood pressure. Acts as a
CC       cysteine-protein sulfhydrase by mediating sulfhydration of target
CC       proteins: sulfhydration consists of converting -SH groups into
CC       -SSH on specific cysteine residues of target proteins such as
CC       GAPDH, PTPN1 and NF-kappa-B subunit RELA, thereby regulating their
CC       function. {ECO:0000269|PubMed:19019829,
CC       ECO:0000269|PubMed:19261609, ECO:0000269|PubMed:22169477}.
CC   -!- CATALYTIC ACTIVITY: L-cystathionine + H(2)O = L-cysteine + NH(3) +
CC       2-oxobutanoate. {ECO:0000269|PubMed:10212249,
CC       ECO:0000269|PubMed:19019829}.
CC   -!- COFACTOR:
CC       Name=pyridoxal 5'-phosphate; Xref=ChEBI:CHEBI:597326;
CC         Evidence={ECO:0000269|PubMed:10212249,
CC         ECO:0000269|PubMed:18476726, ECO:0000269|PubMed:19019829};
CC   -!- ENZYME REGULATION: Inhibited by propargylglycine, trifluoroalanine
CC       and aminoethoxyvinylglycine. {ECO:0000269|PubMed:10212249,
CC       ECO:0000269|PubMed:19019829}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.5 mM for L-cystathionine {ECO:0000269|PubMed:10212249,
CC         ECO:0000269|PubMed:18476726};
CC         KM=5.4 mM for homocysteine {ECO:0000269|PubMed:10212249,
CC         ECO:0000269|PubMed:18476726};
CC         KM=3.5 mM for cysteine {ECO:0000269|PubMed:10212249,
CC         ECO:0000269|PubMed:18476726};
CC       pH dependence:
CC         Optimum pH is 8.2. {ECO:0000269|PubMed:10212249,
CC         ECO:0000269|PubMed:18476726};
CC   -!- PATHWAY: Amino-acid biosynthesis; L-cysteine biosynthesis; L-
CC       cysteine from L-homocysteine and L-serine: step 2/2.
CC   -!- SUBUNIT: Homotetramer. Interacts with CALM in a calcium-dependent
CC       manner (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-749763, EBI-749763;
CC       Q96NT3:GUCD1; NbExp=3; IntAct=EBI-749763, EBI-8293751;
CC       Q6P9E2:RECK; NbExp=5; IntAct=EBI-749763, EBI-10253121;
CC       Q96HA8:WDYHV1; NbExp=3; IntAct=EBI-749763, EBI-741158;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P32929-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P32929-2; Sequence=VSP_006306;
CC       Name=3;
CC         IsoId=P32929-3; Sequence=VSP_047274;
CC   -!- DISEASE: Cystathioninuria (CSTNU) [MIM:219500]: Autosomal
CC       recessive phenotype characterized by abnormal accumulation of
CC       plasma cystathionine, leading to increased urinary excretion.
CC       {ECO:0000269|PubMed:12574942, ECO:0000269|PubMed:18476726}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the trans-sulfuration enzymes family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S52784; AAB24700.1; -; mRNA.
DR   EMBL; S52028; AAB24699.1; -; mRNA.
DR   EMBL; BT006882; AAP35528.1; -; mRNA.
DR   EMBL; AK303946; BAG64874.1; -; mRNA.
DR   EMBL; AK223376; BAD97096.1; -; mRNA.
DR   EMBL; AL354872; CAC12901.1; -; Genomic_DNA.
DR   EMBL; AL354872; CAC12902.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX06450.1; -; Genomic_DNA.
DR   EMBL; BC015807; AAH15807.1; -; mRNA.
DR   CCDS; CCDS53333.1; -. [P32929-3]
DR   CCDS; CCDS650.1; -. [P32929-1]
DR   CCDS; CCDS651.1; -. [P32929-2]
DR   PIR; JC1362; JC1362.
DR   RefSeq; NP_001177392.1; NM_001190463.1. [P32929-3]
DR   RefSeq; NP_001893.2; NM_001902.5. [P32929-1]
DR   RefSeq; NP_714964.2; NM_153742.4. [P32929-2]
DR   UniGene; Hs.19904; -.
DR   PDB; 2NMP; X-ray; 2.60 A; A/B/C/D=1-402.
DR   PDB; 3COG; X-ray; 2.00 A; A/B/C/D=1-402.
DR   PDB; 3ELP; X-ray; 2.40 A; A/B/C/D=1-405.
DR   PDB; 5EIG; X-ray; 2.70 A; A/B/C/D/E/F/G/H=1-405.
DR   PDBsum; 2NMP; -.
DR   PDBsum; 3COG; -.
DR   PDBsum; 3ELP; -.
DR   PDBsum; 5EIG; -.
DR   ProteinModelPortal; P32929; -.
DR   SMR; P32929; -.
DR   BioGrid; 107873; 49.
DR   IntAct; P32929; 6.
DR   MINT; MINT-1479767; -.
DR   STRING; 9606.ENSP00000359976; -.
DR   BindingDB; P32929; -.
DR   DrugBank; DB02328; 2-[(3-Hydroxy-2-Methyl-5-Phosphonooxymethyl-Pyridin-4-Ylmethyl)-Imino]-5-Phosphono-Pent-3-Enoic Acid.
DR   DrugBank; DB04217; L-2-amino-3-butynoic acid.
DR   DrugBank; DB00151; L-Cysteine.
DR   DrugBank; DB00114; Pyridoxal Phosphate.
DR   GuidetoPHARMACOLOGY; 1444; -.
DR   iPTMnet; P32929; -.
DR   PhosphoSitePlus; P32929; -.
DR   BioMuta; CTH; -.
DR   DMDM; 27735163; -.
DR   EPD; P32929; -.
DR   MaxQB; P32929; -.
DR   PaxDb; P32929; -.
DR   PeptideAtlas; P32929; -.
DR   PRIDE; P32929; -.
DR   DNASU; 1491; -.
DR   Ensembl; ENST00000346806; ENSP00000311554; ENSG00000116761. [P32929-2]
DR   Ensembl; ENST00000370938; ENSP00000359976; ENSG00000116761. [P32929-1]
DR   Ensembl; ENST00000411986; ENSP00000413407; ENSG00000116761. [P32929-3]
DR   GeneID; 1491; -.
DR   KEGG; hsa:1491; -.
DR   UCSC; uc001dfd.4; human. [P32929-1]
DR   CTD; 1491; -.
DR   DisGeNET; 1491; -.
DR   GeneCards; CTH; -.
DR   HGNC; HGNC:2501; CTH.
DR   HPA; HPA021591; -.
DR   HPA; HPA023300; -.
DR   MalaCards; CTH; -.
DR   MIM; 219500; phenotype.
DR   MIM; 607657; gene.
DR   neXtProt; NX_P32929; -.
DR   OpenTargets; ENSG00000116761; -.
DR   Orphanet; 212; Cystathioninuria.
DR   PharmGKB; PA27004; -.
DR   eggNOG; KOG0053; Eukaryota.
DR   eggNOG; COG0626; LUCA.
DR   GeneTree; ENSGT00390000000312; -.
DR   HOGENOM; HOG000246415; -.
DR   HOVERGEN; HBG005322; -.
DR   InParanoid; P32929; -.
DR   KO; K01758; -.
DR   OMA; SPIDCYL; -.
DR   OrthoDB; EOG091G0C7Z; -.
DR   PhylomeDB; P32929; -.
DR   TreeFam; TF300720; -.
DR   BioCyc; MetaCyc:HS04050-MONOMER; -.
DR   BRENDA; 4.4.1.1; 2681.
DR   Reactome; R-HSA-1614558; Degradation of cysteine and homocysteine.
DR   Reactome; R-HSA-1614603; Cysteine formation from homocysteine.
DR   Reactome; R-HSA-2408508; Metabolism of ingested SeMet, Sec, MeSec into H2Se.
DR   SABIO-RK; P32929; -.
DR   UniPathway; UPA00136; UER00202.
DR   ChiTaRS; CTH; human.
DR   EvolutionaryTrace; P32929; -.
DR   GenomeRNAi; 1491; -.
DR   PRO; PR:P32929; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000116761; -.
DR   CleanEx; HS_CTH; -.
DR   Genevisible; P32929; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0016846; F:carbon-sulfur lyase activity; TAS:Reactome.
DR   GO; GO:0004123; F:cystathionine gamma-lyase activity; IDA:UniProtKB.
DR   GO; GO:0003962; F:cystathionine gamma-synthase activity; IBA:GO_Central.
DR   GO; GO:0047982; F:homocysteine desulfhydrase activity; TAS:Reactome.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0080146; F:L-cysteine desulfhydrase activity; TAS:Reactome.
DR   GO; GO:0044540; F:L-cystine L-cysteine-lyase (deaminating); IMP:UniProtKB.
DR   GO; GO:0030170; F:pyridoxal phosphate binding; IDA:UniProtKB.
DR   GO; GO:0071266; P:'de novo' L-methionine biosynthetic process; IBA:GO_Central.
DR   GO; GO:0019344; P:cysteine biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0019343; P:cysteine biosynthetic process via cystathionine; IDA:BHF-UCL.
DR   GO; GO:0006534; P:cysteine metabolic process; TAS:ProtInc.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; TAS:UniProtKB.
DR   GO; GO:0070814; P:hydrogen sulfide biosynthetic process; IDA:UniProtKB.
DR   GO; GO:2001234; P:negative regulation of apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:1904831; P:positive regulation of aortic smooth muscle cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IEA:Ensembl.
DR   GO; GO:0051289; P:protein homotetramerization; IPI:UniProtKB.
DR   GO; GO:0044524; P:protein sulfhydration; IMP:UniProtKB.
DR   GO; GO:0018272; P:protein-pyridoxal-5-phosphate linkage via peptidyl-N6-pyridoxal phosphate-L-lysine; IDA:UniProtKB.
DR   GO; GO:0000098; P:sulfur amino acid catabolic process; TAS:Reactome.
DR   GO; GO:0019346; P:transsulfuration; IDA:BHF-UCL.
DR   CDD; cd00614; CGS_like; 1.
DR   Gene3D; 3.40.640.10; -; 1.
DR   Gene3D; 3.90.1150.10; -; 1.
DR   InterPro; IPR000277; Cys/Met-Metab_PyrdxlP-dep_enz.
DR   InterPro; IPR015424; PyrdxlP-dep_Trfase.
DR   InterPro; IPR015421; PyrdxlP-dep_Trfase_major_sub1.
DR   InterPro; IPR015422; PyrdxlP-dep_Trfase_sub2.
DR   PANTHER; PTHR11808; PTHR11808; 1.
DR   Pfam; PF01053; Cys_Met_Meta_PP; 1.
DR   PIRSF; PIRSF001434; CGS; 1.
DR   SUPFAM; SSF53383; SSF53383; 1.
DR   PROSITE; PS00868; CYS_MET_METAB_PP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Amino-acid biosynthesis;
KW   Calmodulin-binding; Complete proteome; Cysteine biosynthesis;
KW   Cytoplasm; Disease mutation; Lyase; Polymorphism; Pyridoxal phosphate;
KW   Reference proteome.
FT   CHAIN         1    405       Cystathionine gamma-lyase.
FT                                /FTId=PRO_0000114749.
FT   BINDING      62     62       Substrate.
FT   BINDING     114    114       Substrate.
FT   BINDING     119    119       Substrate.
FT   BINDING     339    339       Substrate.
FT   MOD_RES     212    212       N6-(pyridoxal phosphate)lysine.
FT                                {ECO:0000250}.
FT   VAR_SEQ      85    116       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_047274.
FT   VAR_SEQ     153    196       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:1339280}.
FT                                /FTId=VSP_006306.
FT   VARIANT      67     67       T -> I (in CSTNU; reduces catalytic
FT                                activity and affinity for pyridoxal
FT                                phosphate; dbSNP:rs28941785).
FT                                {ECO:0000269|PubMed:12574942,
FT                                ECO:0000269|PubMed:18476726}.
FT                                /FTId=VAR_015450.
FT   VARIANT     240    240       Q -> E (in CSTNU; strongly reduces
FT                                catalytic activity and affinity for
FT                                pyridoxal phosphate; dbSNP:rs28941786).
FT                                {ECO:0000269|PubMed:12574942,
FT                                ECO:0000269|PubMed:18476726}.
FT                                /FTId=VAR_015451.
FT   VARIANT     403    403       S -> I (in dbSNP:rs1021737).
FT                                {ECO:0000269|PubMed:12574942,
FT                                ECO:0000269|PubMed:1339280,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_015452.
FT   HELIX        18     24       {ECO:0000244|PDB:3COG}.
FT   HELIX        29     31       {ECO:0000244|PDB:3COG}.
FT   STRAND       36     38       {ECO:0000244|PDB:3COG}.
FT   STRAND       45     47       {ECO:0000244|PDB:5EIG}.
FT   TURN         61     63       {ECO:0000244|PDB:3COG}.
FT   HELIX        66     79       {ECO:0000244|PDB:3COG}.
FT   STRAND       82     88       {ECO:0000244|PDB:3COG}.
FT   HELIX        90     98       {ECO:0000244|PDB:3COG}.
FT   STRAND      106    112       {ECO:0000244|PDB:3COG}.
FT   HELIX       115    123       {ECO:0000244|PDB:3COG}.
FT   HELIX       125    128       {ECO:0000244|PDB:3COG}.
FT   STRAND      131    135       {ECO:0000244|PDB:3COG}.
FT   HELIX       140    146       {ECO:0000244|PDB:3COG}.
FT   STRAND      151    159       {ECO:0000244|PDB:3COG}.
FT   TURN        161    163       {ECO:0000244|PDB:3COG}.
FT   HELIX       169    176       {ECO:0000244|PDB:3COG}.
FT   STRAND      178    180       {ECO:0000244|PDB:3COG}.
FT   STRAND      183    187       {ECO:0000244|PDB:3COG}.
FT   TURN        189    191       {ECO:0000244|PDB:3COG}.
FT   TURN        193    195       {ECO:0000244|PDB:3COG}.
FT   TURN        198    202       {ECO:0000244|PDB:3COG}.
FT   STRAND      204    209       {ECO:0000244|PDB:3COG}.
FT   TURN        210    215       {ECO:0000244|PDB:3COG}.
FT   STRAND      223    227       {ECO:0000244|PDB:3COG}.
FT   HELIX       230    243       {ECO:0000244|PDB:3COG}.
FT   HELIX       249    259       {ECO:0000244|PDB:3COG}.
FT   HELIX       262    281       {ECO:0000244|PDB:3COG}.
FT   STRAND      286    290       {ECO:0000244|PDB:3COG}.
FT   HELIX       300    306       {ECO:0000244|PDB:3COG}.
FT   STRAND      312    320       {ECO:0000244|PDB:3COG}.
FT   HELIX       322    331       {ECO:0000244|PDB:3COG}.
FT   STRAND      333    337       {ECO:0000244|PDB:3COG}.
FT   STRAND      342    345       {ECO:0000244|PDB:3COG}.
FT   STRAND      347    349       {ECO:0000244|PDB:3COG}.
FT   TURN        351    358       {ECO:0000244|PDB:3COG}.
FT   HELIX       361    367       {ECO:0000244|PDB:3COG}.
FT   STRAND      373    377       {ECO:0000244|PDB:3COG}.
FT   HELIX       383    397       {ECO:0000244|PDB:3COG}.
SQ   SEQUENCE   405 AA;  44508 MW;  003246D7C1D16723 CRC64;
     MQEKDASSQG FLPHFQHFAT QAIHVGQDPE QWTSRAVVPP ISLSTTFKQG APGQHSGFEY
     SRSGNPTRNC LEKAVAALDG AKYCLAFASG LAATVTITHL LKAGDQIICM DDVYGGTNRY
     FRQVASEFGL KISFVDCSKI KLLEAAITPE TKLVWIETPT NPTQKVIDIE GCAHIVHKHG
     DIILVVDNTF MSPYFQRPLA LGADISMYSA TKYMNGHSDV VMGLVSVNCE SLHNRLRFLQ
     NSLGAVPSPI DCYLCNRGLK TLHVRMEKHF KNGMAVAQFL ESNPWVEKVI YPGLPSHPQH
     ELVKRQCTGC TGMVTFYIKG TLQHAEIFLK NLKLFTLAES LGGFESLAEL PAIMTHASVL
     KNDRDVLGIS DTLIRLSVGL EDEEDLLEDL DQALKAAHPP SGSHS
//
